New Therapies in Development for Multiple Myeloma
In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.
Joseph R. Mikhael, MD, of the Mayo Clinic in Arizona, discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development for multiple myeloma, both for treatment-naive and relapsed refractory patients, including the next-generation novel proteasome inhibitors, ixazomib (MLN9708) and oprozomib. Dr. Mikhael also highlights several monoclonal antibodies.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
